Resolution of Organ Injury in Acute Pancreatitis - RESORP

Pancreatitis, Acute Clinical Trial

— RESORP  

Official title:

Resolution of Organ Injury in Acute Pancreatitis - RESORP

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03342716
• Other study ID #: v11 23 Sept 2019
• Secondary ID: MR/P008887/1
• Status: Completed
• Start date: November 27, 2017
• Est. completion date: February 16, 2022

Study information

• Verified date: February 2022
• Source: University of Edinburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Acute pancreatitis (AP) is inflammation of the pancreas usually triggered by gallstones or drinking excessive alcohol. 80% of people who have an episode of AP will recover without complications. However, 20% will require treatment in high dependency or intensive care for multiple organ dysfunction (AP-MODS). It is known that this negatively affects recovery and can have a lasting effect on health although it is incompletely understood what causes this.

Aim: To recruit 500 patients with acute pancreatitis. Participants will be assessed at recruitment and and again at 3 and 36 months. Recovery of organ function will be serially measured and the presence of novel factors important in recovery assessed.

Description:

Acute pancreatitis (AP) is a common and devastating disease with an annual incidence of 22-30 per 100,000 in the UK. The incidence is increasing. AP is most commonly triggered by gallstones or alcohol excess and has a range of outcomes, from complete resolution to death, with an overall mortality in Scotland of 5.2%. AP is characterised by acute inflammation of the pancreas, which initiates a cascade of inflammatory events throughout the body that can lead to multiple organ dysfunction syndrome (MODS) in approximately 25% of AP patients. Mortality in AP is greatest in those patients who develop MODS, with death rates reported to be up to 28%.

The development of persistent organ failure characterises severe AP (SAP) as defined in the revised Atlanta classification, and is strongly predictive of a fatal outcome. A significant proportion of research has focussed on reducing mortality and morbidity in the first week. As a consequence, it remains to be seen whether the patterns of early organ dysfunction are reflected in the causes of long-term mortality and morbidity.

Recently published data from a retrospective analysis of patients admitted to the Royal Infirmary of Edinburgh with acute pancreatitis has shown that the early development of MODS is associated with an increased mortality rate up to 10 years after the index presentation. This strongly suggests that MODS in acute pancreatitis (AP-MODS) has a persistent and deleterious impact on patients' physiological status, though the exact nature of this pathology remains to be characterised. Recent data has indicated that the severity of the first attack of AP significantly influences the risk of progression to chronic pancreatitis, and therefore subsequent long-term morbidity.

This observational clinical cohort study aims to characterise the nature and extent of the pathophysiological impact of SAP on organ function over the first 3 years following the index event and the long-term deleterious effect of SAP. This will be achieved by prospectively evaluating the pathophysiological consequences of an episode of AP by measuring organ system function in patients recruited during a hospital admission with AP. We will obtain an in-depth assessment of patients' health at presentation, and at 3 months and 36 months after the first episode of AP using markers of organ function and/or disease in the peripheral blood. In a nested cohort within the main study cohort, we will conduct cardiorespiratory evaluation tests (including exercise testing), specialised blood tests of the immune system, tests for precision medicine, and imaging to assess structure and function of key organ systems.

The results of this study will inform the design of future interventions designed to improve the long-term prognosis of patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 229
• Est. completion date: February 16, 2022
• Est. primary completion date: January 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

All patients treated at Royal Infirmary Edinburgh with a clinical or radiological diagnosis of acute pancreatitis will be recruited where possible.

For the potential clinical diagnosis of acute pancreatitis an appropriate clinical history based on compatible clinical features, will be required (i.e. abdominal pain, nausea and/or vomiting), supported by the finding of elevated serum amylase greater than 3x the upper limit of the reference range for the laboratory (currently 300 U/L).

For the radiological diagnosis, if applicable, computerised tomography (CT) and/or ultrasound scan (USS) evidence of acute pancreatitis will be accepted.

Exclusion Criteria:

The following exclusion criteria will be adhered to:

i. Patients under the age of 16 years will be excluded from the present study. ii. Prisoners will be excluded from the present study. iii. Patients lacking the capacity to consent will be excluded but can be included if they regain capacity.

Additional exclusions will apply only to those patients being considered for the nested cohort study:

iv. Patients not able to undergo MRI scanning for technical reasons will be excluded (e.g. those with cochlear implants, implanted pacemaker) v. Patients with a known allergy to salbutamol

Related Conditions & MeSH terms

• Pancreatitis
• Pancreatitis, Acute

Locations

Country	Name	City	State
United Kingdom	Royal Infirmary of Edinburgh	Edinburgh

Sponsors (2)

Lead Sponsor	Collaborator
University of Edinburgh	Medical Research Council

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Annual incidence of new-onset type 3c diabetes mellitis in patients with AP	Do patients that have had AP develop type 3c diabetes mellitis more frequently?	66 months
Primary	Nested cohort only - difference in the 3 month to 36 month change in pancreatic fibrosis index between participants with AP with MODS and those with AP without MODS	Assess any damage to pancreas at 3 and 36 months and monitor how this changes throughout the course of the trial comparing participants with AP only and those with AP and MODS	66 months
Secondary	Specific gene and promoter sequence variation between participants with AP and AP-MODS	Define any gene and promoter sequence variation between participants with AP and AP-MODS; machine learning approach	66 months
Secondary	miRNA signatures of disease severity and resolution	Comparing patterns of gene expression in mild/moderate/severe cases of AP; machine learning approach	66 months
Secondary	Metabolomic profiling of AP resolution.	Comparing patterns of metabolite expression in mild/moderate/severe cases of AP; machine learning approach	66 months
Secondary	Incidence of premature cellular senescence as a pathological consequence of AP-MODS.	Investigating pathological consequences of AP-MODS compared to AP without MODS	66 months
Secondary	Alteration in immune cell subset phenotype as a long-term response to AP-MODS	Investigating changes to the phenotype of immune cell subsets following an episode of AP; descriptive statistics	66 months
Secondary	Cardiorespiratory dysfunction as a legacy of endothelial injury during AP-MODS	Determination of cardiorespiratory function following AP using physiological measures including cardiopulmonary exercise testing to determine anaerobic threshold. Descriptive measures.	66 months

External Links

•   Protocol publication